Follitropin alfa sustained-release - Alkermes/Serono

Drug Profile

Follitropin alfa sustained-release - Alkermes/Serono

Alternative Names: Follitropin alfa-ProLease formulation - Alkermes/Serono; GONAL-f® micoencapsulated; Microencapsulated follitropin alfa; Microencapsulated rhFSH; ProLease® formulation rhFSH

Latest Information Update: 09 May 2005

Price : $50

At a glance

  • Originator Merck Serono
  • Developer Alkermes
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility; Male infertility

Most Recent Events

  • 30 Oct 2004 Discontinued - Phase-I for Male infertility in USA (SC)
  • 30 Oct 2004 Discontinued - Phase-I for Female infertility in USA (SC)
  • 24 Sep 2002 Phase-I clinical trials in Female infertility in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top